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ABSTRACT
MiRNAs are increasingly recognized as biomarkers for the diagnosis of cancers 
where they are profiled from tumor tissue (intracellular miRNAs) or serum/plasma 
samples (extracellular miRNAs). To improve detection of reliable biomarkers from 
blood samples, we first compiled a healthy reference miRNome and established a 
well-controlled analysis pipeline allowing for standardized quantification of circulating 
miRNAs. Using whole miRNome and custom qPCR arrays, miRNA expression profiles 
were analyzed in 126 serum, whole blood and tissue samples of healthy volunteers and 
melanoma patients and in primary melanocyte and keratinocyte cell lines. We found 
characteristic signatures with excellent prognostic scores only in late stage but not in 
early stage melanoma patients. Upon comparison of melanoma tissue miRNomes with 
matching serum samples, several miRNAs were identified to be exclusively tissue-
derived (miR-30b-5p, miR-374a-5p and others) while others had higher expression 
levels in serum (miR-3201 and miR-122-5p). Here we have compiled a healthy and 
widely applicable miRNome from serum samples and we provide strong evidence 
that levels of cell-free miRNAs only change significantly at later stages of melanoma 
progression, which has serious implications for miRNA biomarker studies in cancer.
INTRODUCTION
A key prerequisite to any successful cancer therapy 
is its early diagnosis. In order to detect malignancies as 
early as possible, a large number of tailored laboratory 
tests for detection of marker proteins, metabolites, specific 
mutations and imaging of concerned body regions as 
well as biomarker profiling are routinely used in various 
clinical settings (Cancer Facts and Figures, American 
Cancer Society, 2014).
Biomarkers are defined as “a characteristic that 
is objectively measured and evaluated as an indicator 
of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” 
[1]. As such, biomarkers are quantitative and robust 
measures that allow for unequivocal diagnosis of a 
specific disease, for assessing progression of disease or for 
monitoring response to treatment. The remarkable stability 
and tissue-specific expression profiles of miRNAs have 
raised hopes that these small non-coding nucleic acids 
could represent useful biomarkers that characteristically 
change their expression profiles in tissue and/or blood 
samples upon development and progression of cancer [2-
4]. Since the first report about the potential of circulating 
miRNAs as biomarkers [5], many studies have reported 
cancer type-specific miRNA signatures [6-8]. 
Melanoma is one of few cancer entities with 
increasing case numbers almost anywhere in the world. 
Considerable therapeutical progress has been made in 
recent years with the introduction of specific kinase 
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inhibitors targeting constitutively active BRAF present in 
more than 50% of melanoma patients. However, most such 
treated patients rapidly develop resistance against the drug 
requiring new and better therapies [9]. In a novel clinical 
approach, immunotherapies targeting immune checkpoint 
inhibitors CTLA-4 and PD-1 have been developed that 
show promising results in ongoing clinical trials [10]. 
However, the long term survival benefit for patients still 
remains to be established [11].
Given the clinical importance of melanoma, several 
research laboratories have ventured into quantification of 
miRNAs from blood, serum or plasma samples [12-17]. 
However, using different profiling platforms and inputs 
and variable techniques for quality control, normalisation 
and statistical evaluation, reported results show very 
limited congruence. Along these lines and regardless of 
the many publications claiming identification of specific 
miRNA biomarkers for cancer, several critical voices 
have recently summarised the technical and biological 
challenges of circulating miRNA profiling studies and 
they all together highlight the lack of consistency among 
published miRNA cancer signatures [6, 7, 18-25]. 
A major obstacle in miRNA profiling comes from 
technical issues related to the choice of platform and 
data analysis. Using qPCR array technology together 
with strict quality control measures at all steps of sample 
handling, data generation, processing and interpretation, 
we have compared serum-and tissue-derived miRNomes 
from healthy volunteers to melanoma patient samples 
representing all stages of disease. 
Blood samples are an optimal source for detection 
of biomarkers. However, in order to achieve reproducible 
results, a healthy counterpart is necessary, representing a 
stable baseline against which changing miRNA profiles 
can be compared to. To our knowledge, no blood-based 
healthy miRNome is yet available in public databases 
comprising individuals from different ethnicities, gender 
and age. Here, we began to compile such a healthy 
miRNome, which can serve as a reference for secreted 
miRNA profiles to study melanoma or other cancers and 
diseases. A total of 52 melanoma patient serum samples 
and 30 healthy counterparts were analysed: statistically 
significant changes in the miRNome were only found at 
late stages of disease when advanced metastasis changes 
the integrity of body tissues. Furthermore, miRNA 
expression patterns were compared between melanoma 
tissues and blood samples, which revealed a subset of 
selectively secreted miRNAs. 
RESULTS AND DISCUSSION
Study design and quality control 
Fig. 1 summarises the study design, the number 
and types of samples analysed by whole miRNome qPCR 
arrays and by customized qPCR arrays representing 88 
miRNAs, selected to serve as potential biomarkers for the 
diagnosis of melanoma. Here, extensive quality control 
steps for sample collection, processing, data acquisition 
and analysis were applied in order to obtain robust and 
reproducible results, indicating whether secreted miRNAs 
could indeed be suitable biomarkers for melanoma. We 
chose a qPCR array platform with pre-amplification of 
mature miRNAs suitable for quantification of the typically 
low miRNA amounts in cell-free samples. Previous in-
house data with hybridization microarrays and RNA-Seq 
revealed that qPCR would be the most useful technique 
for this purpose. In accordance, a recent comprehensive 
comparison of 12 commercially available miRNA 
profiling platforms also showed qPCR arrays to perform 
well in terms of reproducibly, sensitively and specifically 
quantifying low copy number miRNAs [26]. 
First, we compared sample types and found 
no major differences between serum and plasma 
(Supplementary Fig. S1A). To allow for inter-sample 
comparisons and to control for RNA extraction efficiency, 
we added exogenous RNAs (cel-39, cel-238 and cel-54) 
at different ratios (Supplementary Fig. S1B). Furthermore, 
RNA extraction protocols were optimized for precipitation 
of low miRNA amounts. RNA carriers introduced a 
bias and were therefore not used (Supplementary Fig. 
S1C). Cel-39 expression levels were used to calibrate 
data. Subsequently, we applied a protocol to control for 
potential contaminating miRNAs derived from platelets, 
lymphocytes and/or erythrocytes in each serum sample 
[27]. Samples showing hemolysis or the presence of 
contaminating blood cell-derived miRNAs were not 
considered for the study. Next, we established that pre-
amplification was required to analyze all 1066 miRNAs 
by qPCR arrays (Supplementary Fig. S1D). Tests using 
selected miRNAs determined the general amplification 
factor between non- and pre-amplified templates to be 250-
fold (Supplementary Fig. S1E). Additional experiments 
showed a good correlation between manual and whole 
miRNome qPCR (Supplementary Fig. S1F). Finally, a 
novel bioinformatic tool was developed allowing for 
rapid analysis of thousands of melting curves, a necessary 
quality control step for SYBR-green based qPCR 
amplifications (which is often omitted in many published 
studies) before analysis of differential expression can be 
performed. MiRNAs with bad melt curves, indicating 
unspecific amplification despite sometimes low Cq values, 
were disregarded.
Due to the lack of stable reference miRNAs in 
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Figure 1: Overview of study design. Numbers in brackets indicate number of separate samples included in pools. Individual melanoma 
patient serum samples analysed on custom qPCR arrays comprise 4 stage 0, 11 stage I, 17 stage II, 11 stage III and 9 stage IV samples. 
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serum samples, data normalisation and analysis pose a 
challenge. Noteworthy, miR-16-5p and RNU6B, which 
are regularly used for normalisation of miRNA expression 
levels in cell-free samples [6, 28] were either unstable 
(especially in slightly hemolytic samples, miR-16-5p) 
or absent (RNU6-2) in our data sets (data not shown). 
In Materials and Methods, a detailed description of the 
different approaches for data analysis is provided. Taken 
together, we invested considerable effort to set up an 
analysis pipeline that allows for sensitive and specific 
quantification of miRNAs in cell-free samples.
The healthy miRNome 
Given the lack of suitable small reference RNAs 
in cell-free samples and considering that most miRNA 
expression changes are notoriously small, a standardized 
healthy miRNome serving as a “baseline control” for 
all profiling studies is essential. Similar to the reference 
genome, which is composed of sequences from different 
individuals, we have started to assemble a healthy 
miRNome, using serum samples from 23 healthy 
individuals including 4 volunteers where blood samples 
were drawn at different times of day (circadian sample 
set). MiRNome data were collected by qPCR arrays and 
expression values for each miRNA were calculated with 
the aim to detect miRNAs that fluctuate between healthy 
individuals, of which we found 30 (3% of 1066 analysed 
miRNAs, Fig. 2A). These fluctuating miRNAs should be 
interpreted with care if identified in any kind of differential 
miRNA expression analysis.
In order to control for possible effects that the 
time of sample collection could have on the stability 
of the miRNome, samples were collected at different 
times of day (circadian samples). No major expression 
changes were identified when we looked for miRNAs 
that showed higher expression at one time point only. 
Only 7 miRNAs (0.9% of 1066, Fig. 2B) showed modest 
augmentation after lunch suggesting that these could be 
potential circadian and/or metabolic miRNA candidates 
associated with uptake of food. The lack of circadian cycle 
expression changes in circulating miRNAs was intriguing 
and similar to what has recently been described by Keller 
and colleagues [29]. On the other hand, miRNAs have 
been shown to post-transcriptionally regulate expression 
levels of circadian clock genes and change with age [30-
32]. 
In summary, we compiled a reference data set 
(Supplementary Table S2) representing a remarkably 
stable secreted cell-free miRNome. Sixty-three % of 
miRNAs were not expressed in serum samples, 3% 
fluctuated between individuals and only 8% (82 miRNAs 
with a Cq value below 27 in 80% of samples) showed high 
expression values in serum samples (Fig. 2C). To make 
the healthy secreted miRNome as robust as possible we 
are continuing to collect samples for the healthy cohort. 
miRNA profiling of melanoma samples 
The heatmap in Fig. 3A shows an overview of 
whole miRNome data sets for melanoma tissue samples 
(discussed below), normal human primary melanocytes 
(NHEM) and keratinocytes (NHEK) as well as for healthy 
individuals and melanoma patient serum samples. Three 
whole blood sample pools representing healthy, early and 
late stage melanoma patients have remarkably similar 
expression patterns while they were clearly distinct 
from serum samples. Overall, normal skin, primary 
lesion and metastatic melanoma tissue samples were 
well discernible. Of note, two of the primary melanoma 
tissues (MP-39.PM and MP-43.PM) resemble the only 
two metastatic melanoma samples included here (MP-
51.MET and MP-39.MET) possibly suggesting a more 
advanced tumor stage. Skin tissue samples always 
contain a varying amount of keratinocytes. To account 
for the intrinsic heterogeneity of tissue samples, we also 
analysed primary cell lines of keratinocytes (NHEK) and 
melanocytes (NHEM), which show discrete expression 
levels for several miRNAs and this could help to allocate 
expression profiles of individual miRNAs from melanoma 
tissue samples to the respective cell types. Overall, the 
whole miRNome data separate sample types as such 
that whole blood samples, primary cell lines, tissue and 
serum samples show distinct expression patterns with 
the expression levels of most miRNAs being very low 
or absent in serum samples (also see Fig. 2C). Therefore, 
we opted for custom-made qPCR arrays that contain only 
the most interesting miRNAs for the current study. Fig. 
3B depicts relative expressions of 87 miRNAs (excluding 
miR-374c-5p that was absent in all samples) in 82 serum 
samples (30 healthy-green; 52 melanoma-red; 52 female-
pink; 30 male-blue). The heatmap, PCA and t-SNE 
plots (Fig. 3C) illustrate that no clustering according to 
healthy versus melanoma or gender was evident. Overall, 
variations in expression levels of individual miRNAs were 
relatively low with few exceptions (e.g. miR-127-3p, miR-
337-3p). 
To confirm the absence of clustering according to 
gender, we averaged the expression values of all miRNAs 
on the custom arrays for female and male samples 
(Supplementary Fig. S2A). Next, we separated the data 
sets into healthy and melanoma samples. Supplementary 
Fig. S2B reveals that the healthy miRNomes display 
similar expression profiles for most miRNAs. In contrast, 
the 52 melanoma serum samples show a more or less 
random distribution with no obvious grouping according 
to disease stage (Supplementary Fig. S2C). 
To nevertheless allow for identification of potential 
disease stage-specific miRNAs, we combined these 
samples according to their cancer stage and compared 
them to the average of the healthy samples (Fig. 4A). The 
different groups revealed distinct expression patterns, 
which prompted us to find signature miRNAs, potentially 
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characteristic for the different stages of melanoma. First, 
accuracy values were computed to identify the optimal 
number of miRNAs required to make correct stage 
assignments. Then, AUC values were calculated for the 
different groups (Fig. 4B). Results from heatmaps and 
ROC curve analysis correlated well. Fig. 4B shows that 
upon comparison of healthy individuals with stage III or 
IV metastatic melanoma samples, biomarkers were found 
with excellent predictive scores (AUC 0.99/CI 0.96-1.00 
for stage III and AUC 0.97/ CI 0.89-1.00 for stage IV). 
Several miRNAs were profoundly down-regulated in 
late stage melanoma patients (e.g. miR-200c-3p, -204-
5p, -182-5p, -301a-3p) while others were up-regulated 
(e.g. miR-211-5p, -193b-3p, -720, -205-5p). Six of 
Figure 2: The secreted healthy miRNome. A) Stability of the healthy miRNome. Mean-standard deviation plots of averaged raw 
Cq values or normalized expression for 1066 miRNAs (qPCR arrays of 3 serum pools (from 19 individual healthy donors) and circadian 
serum samples from 4 individuals). 30 miRNAs (list) with a STD above 1 for Cq values (red dots) were determined as unstable. MiRNAs 
absent in all samples as well as the averaged healthy miRNome are shown in Supplementary Table S2. B) Analysis of circadian miRNomes. 
Twelve serum samples of 4 volunteers collected at different times of day were compared to the healthy miRNome. Fold changes +/- SD 
were calculated for miRNAs that had a measurable higher or lower expression at one time point only (midday). c) Pie chart summarising 
data of the healthy miRNomes. NA: not expressed (Cq values >30 in all samples), MC: bad melt curves in more than 80% of samples, low 




these potential biomarkers were also described to be 
differentially regulated in secreted melanoma exosomes 
compared to healthy melanocytes [33]. Those identified 
miRNAs contain several new candidates as well as 
some miRNAs that have previously been connected to 
melanoma. MiR-211-5p is overexpressed in the plasma of 
late stage melanoma patients [15]. In this context, we have 
recently shown that miR-211-5p has no evident role in 
inhibiting invasion of melanoma cells [34] as was claimed 
before [35-37] and we describe here that indeed miR-211-
5p is highly overexpressed in serum of stage IV melanoma 
patients when compared to healthy controls. In fact, the 
overexpression levels (68-fold) of this miRNA in serum 
samples of stage IV melanoma patients were the highest 
measured throughout the study (data not shown). MiR-
211-5p has long been recognised as a marker miRNA for 
the melanocytic lineage [38, 39] and its high levels in sera 
of late stage patients might suggest that it is specifically 
secreted from melanoma cells. 
Given the clinical importance of melanoma, several 
miRNA quantification studies have been performed 
using tissue, blood, serum or plasma samples in order to 
identify biomarkers that could diagnose or predict disease. 
Greenberg et al. reported miR-29c-5p and miR-324-3p to 
be lower in the serum of metastatic melanoma patients 
(stage IV) compared to healthy control individuals [16]. 
Both miRNAs could discriminate between melanoma and 
colon or renal cancer. A signature of 5 serum miRNAs 
(miR-150-5p, -15b-5p, -199a-5p, -33a-5p, -424-5p) was 
described as biomarkers for recurrence in melanoma [13] 
while Leidinger and colleagues suggested a signature of 16 
miRNAs from whole blood samples that could be used to 
separate melanoma from healthy control samples [14]. We 
found no overlap with our data on whole blood samples 
probably because different platforms and methodologies 
were used (Supplementary Table S3). In another report, 
the oncomiR-21 was found highly expressed in melanoma 
patient plasma matching high expression levels of this 
miRNA in melanoma tissues [15]. Own previous data 
indicated reduced expression levels of miR-200c-3p 
and miR-205-5p in metastatic melanoma tissue samples 
[40]. Levels of miR-182-5p, important for melanoma 
progression, had not been analysed before in serum and 
are shown here to be lower in stage III patients compared 
to healthy volunteers. 
The usefulness of biomarkers should be determined 
not only by their sensitivity and specificity but also by their 
clinical relevance [41]. In case of melanoma, the clinical 
importance of markers for the diagnosis of the malignancy 
is limited as the vast majority of cases can readily be 
diagnosed by visual inspection through a dermatologist 
followed by histological confirmation of excised tissue 
material [42]. However, at very early stages of disease or 
when primary lesions are occult (or during BRAF kinase 
inhibitor treatments), a biomarker test indicative of early 
stage cancer or development of drug resistance would be 
clinically valuable. Here, serum samples from patients 
with metastatic melanoma showed marked expression 
changes in some miRNAs that could qualify as biomarkers 
only at late stages of disease. However, when rigid quality 
control measures were applied, a reliable distinction 
between the healthy miRNome and early stage melanoma 
or melanoma patients overall was not possible. 
In agreement with the recently voiced critical 
thoughts [18, 21], the scientific community will have 
to agree on quality standards and possibly personal 
cutoffs and thresholds [43] for profiling miRNomes 
and quantifying individual miRNAs (similar to the 
MIAME and MIQE rules for microarray and qPCR data, 
respectively) if we are to identify sustainable miRNA 
biomarkers. Otherwise, data from different laboratories 
and studies will remain almost impossible to compare and 
only by adding more data sets, we will not accomplish the 
goal of finding suitable and reliable biomarkers for cancer 
and other diseases.
Comparison of circulating miRNAs with matching 
tissue
To investigate differences in miRNA expression 
related to the type of sample, we compared serum-
and tissue-derived miRNomes from 4 individuals and 
found several miRNAs (of the 88 candidates on custom 
plates) with distinct intracellular and extracellular 
levels (Supplementary Fig. S3). Fig. 5 depicts averaged 
expression levels for available serum, normal skin, primary 
tumour and metastasis samples. Noteworthy, direct and 
accurate comparisons between miRNA expression levels 
in serum and tissue samples remain problematic because 
of the very low RNA amounts in serum samples that 
are difficult to quantify while known and standardized 
amounts are used for amplification from tissues. On the 
other hand, evaluation of same sample types amongst 
individuals is feasible and the whole miRNome heatmap 
(Fig. 3A) shows that the overall expression levels of many 
miRNAs was increased in tissue samples from late stage 
Figure 3: MiRNA profiling of melanoma samples. A) Heatmap of whole miRNome qPCR array data of all 44 samples (see Fig. 
1) normalized by global plate mean (miRNAs absent across all samples are not depicted). WB: whole blood, NS: normal skin tissue, 
MET: metastatic tissue, PM: primary melanoma tissue, st: stage; NHEK: normal human epidermal keratinocyte cell line; NHEM: normal 
human epidermal melanocyte cell line, HY: healthy, HYcd: healthy circadian, MP: melanoma patient, HP: healthy pool, PP: patient pool. * 
represent normal skin, arrows metastatic tissue and “P” indicates primary tumour. B) Heatmap and C) PCA and t-SNE plots of 82 individual 
serum samples (30 healthy volunteers and 52 melanoma patients) analysed by custom qPCR arrays. Data were normalized using the 5 most 
stable miRNAs. Colours: blue-male; pink-female; green-healthy; red-patient. 
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Figure 4: Biomarker studies. A) Heatmap and PCA showing the averages of samples belonging to different melanoma stages and 
healthy serum samples (based on Fig. 3B and 3C). S: stage; hy: healthy. B) ROC curves on pairwise comparisons between indicated sample 
groups (30 healthy, 4 stage 0, 11 stage I, 17 stage II, 11 stage III, 9 stage IV samples; early: stage 0+I+II; late: stage III+IV). Underlined 
miRNAs were upregulated while all others were downregulated compared to healthy or early stage samples. MiRNAs in grey shade should 
not be considered as potential biomarkers because they were highly expressed (Cq < 15) in whole blood samples and might therefore derive 
from contaminating blood cells (miR-1260a, miR-22-3p, miR-1280, miR-451a and miR-16-5p, also see Supplementary Table S3), or they 
were part of the unstable miRNAs (miR-432-3p, miR-373-5p; see Fig. 2A). ACC: accuracy value, AUC: area under the curve. 
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Figure 5: Comparison of tissue and serum samples. Bar diagram showing averaged relative expression values from available serum 
(blue), normal skin (red), primary tumour lesion (green) and metastatic lesions (purple) samples. Arrows indicate gradually increasing 
expression of miRNA with progression of disease, stars highlight miRNAs that were only detected in tissue samples but not in serum, dots 
mark miRNAs with serum expression only. Expression levels of single samples can be seen in Supplementary Fig. S3.
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melanoma patients compared to healthy individuals, 
normal skin samples and primary tumours. 
Fifteen miRNAs (17%) were exclusively found 
intracellularly (marked with a star in Fig. 5) and several 
miRNAs (such as miR-204-5p, -211-5p, 374c-5p, -363-
3p, -483-5p) show a gradual increase in tissue expression 
levels with progression of disease (normal skin → primary 
lesion → metastasis; marked with an arrow). In line with 
previous studies, miR-200c-3p and -205-5p were only 
observed in normal skin but hardly in tumour samples [40, 
44]. Similarly, members of the miR-29 family had higher 
levels in primary tumours than in metastatic samples 
indicating potential tumour-suppressive roles for these 
miRNAs as was described before [45, 46]. MiR-211-5p 
and miR-204-5p belong to the same family sharing most of 
their target genes and have previously been assigned key 
roles in melanoma development [36, 47]. Here, we also 
detected both miRNAs in melanoma tumour tissues. It was 
recently stated that expression levels of a given miRNA 
should correlate between tissue and matching blood 
samples so that high levels of a miRNA in circulation 
should be matched by high levels of this miRNA in the 
respective tissue [18]. However, another scenario is also 
likely in which cancer cells specifically, randomly or by 
unknown processes completely secrete certain miRNAs at 
a given time point. In this case, miRNA levels in tissue 
and in cell-free preparations could be inversely correlated. 
Moreover, serum miRNAs may derive from other tissues 
or organs not necessarily related to the tumour. We found 
12 cases (of 88) where miRNAs had >3-fold higher 
expression level in serum than in tissue and 2 miRNAs 
were exclusively detected in serum (miR-3201 (unknown 
function), miR-122-5p (liver-specific), marked with a dot 
in Fig. 5).
In conclusion, expression profiles for the majority 
of analysed miRNAs in tissue and serum samples from 
the same individuals were similar to each other with only 
16% of miRNAs reaching considerably higher relative 
levels intracellulary than in circulation. Several interesting 
miRNAs have been identified that increase their expression 
levels with stage of disease. However, most of those were 
not detected as serum-based biomarker candidates for late 
stage melanoma patients described above, which once 
again highlights the difficulty to identify robust blood-
based miRNA biomarkers (also see Fig. 4). 
The underlying idea of measuring secreted miRNAs 
in cell-free samples is that the presence of cancer (or other 
diseases) induces changes in the levels of secretion so that 
different amounts and profiles of miRNAs in circulation 
can be translated back to a disease or response to treatment. 
Whether cellular transformation requires the active 
shuttling of miRNAs or whether it is a coincidental “by-
product” of malignancy (released by apoptotic cells) and 
which miRNAs are preferentially secreted via exosomes 
or bound to proteins such as Ago2, is currently unknown. 
Several studies have demonstrated that secreted miRNAs 
can act as intercellular messengers [48-50] and although 
the molecular events are incompletely understood, it is 
tempting to speculate that upon cancer formation, secreted 
miRNAs may play a role in establishing continued growth 
or even metastasis distant from the primary lesion. If this 
is the case, specific intracellular and extracellular patterns 
of miRNAs should be detectable that correspond to 
different cancer entities and stages provided that no other 
confounding diseases blur the picture. MiRNAs, that are 
disease-specifically secreted (via exosomes or bound to 
Ago2) into the blood may convey signals to recipient 
cells, where the engulfed circulating miRNA could then, 
together with endogenously expressed miRNAs, down-
regulate target mRNAs and in doing so participate in 
pathological events. However, only few studies have so 
far demonstrated such a biological function of circulating 
miRNAs [49-52]. 
Apart from expression profiles of secreted miRNAs, 
we also began to investigate the potential functional role 
of such circulating miRNAs. In a first set of experiments 
we isolated exosomes from patients´ sera and proved that 
certain miRNAs (here miR-211) were highly expressed. 
Those miRNA-containing exosomes were then transferred 
to A375 melanoma recipient cells, which are devoid of 
miR-211. Surprisingly, several previously confirmed 
target genes of miR-211 [34] were not found to be down-
regulated in those cells indicating that the amount of 
exosome-transferrable circulating miRNAs might not 
be sufficient to significantly reduce mRNA expression 
levels of target genes in recipient cells (data not shown). 
While this finding requires further confirmation with more 
miRNAs and target genes, it nevertheless provides a first 
indication that the assumed functional role of secreted 
miRNAs as specific paracrine messengers might have to 
be revisited. 
Altogether, our and previous results show that 
several miRNAs are actively shuttled out of cells under 
certain conditions (possibly because the cell has so 
far unidentified mechanisms to rid itself of miRNAs). 
It remains to be shown though whether secreted 
miRNAs could actively partake in transferring signals 
or in functionally down-regulating target mRNAs by 
overwriting or supporting the endogenous miRNAs in 
other target cells. Many factors can confound the levels 
of circulating miRNAs and indeed it remains to be seen 
whether we will soon have developed commonly applied 
sampling, processing and profiling protocols that can 
clearly discriminate between truly secreted miRNAs 
indicative of malignant processes from contaminating 
miRNAs derived from platelets, erythrocytes, lymphocytes 
or normal cell death. In a next step, it needs to be 
established whether such truly secreted miRNAs, once we 
have means to reliably quantify them, may have biological 




Serum and whole blood samples, primary and 
metastatic melanoma tissue and corresponding healthy 
skin samples were collected at the Dermatology Unit of the 
University Hospital in Freiburg, the Dermatology Clinic in 
Dortmund, at the University Hospital in Homburg (all in 
Germany) and at the Red Cross in Luxembourg. Circadian 
samples from healthy individuals were collected in the 
morning (before breakfast), at midday (after lunch) and in 
the early evening (before dinner). Sample collection was 
approved by the respective ethics committees in Germany 
and Luxembourg and written informed consent was 
obtained from all healthy controls and patients. Further 
information on samples is given in Supplementary Table 
S1.
Study design 
Samples were profiled using whole miRNome 
qPCR arrays (Qiagen, miRBase v.16 with 1066 miRNAs). 
In a first step, groups of healthy donors and melanoma 
patient serum samples (representing early or late stage 
melanomas) were pooled to average out individual 
variances and to find robust differences between 
populations or were analysed individually (Fig. 1). From 
this analysis, 88 miRNAs were selected to be spotted on 
customized qPCR arrays (Qiagen, Germany) taking into 
consideration miRNAs differentially expressed between 
healthy and disease samples, several stable miRNAs, 
previous own data as well as interesting miRNAs described 
in literature (Fig. 1 and Supplementary Table S2). A 
further 82 serum samples were subsequently analysed on 
such custom qPCR miRNA arrays. Additionally, qPCR 
data derived from healthy serum samples were used to 
establish a secreted healthy reference miRNome (Fig. 2 
and Supplementary Table S2).
Quality control
The lack of consistent protocols for circulating 
miRNA profiling and the absence of stable secreted 
reference miRNAs leads to a large variability and 
incoherent results reported in different studies. Recent 
publications have highlighted some of the technical 
problems of miRNA biomarker studies [18, 21, 23]. We 
have addressed most of these issues and combined several 
measures to ensure high quality and reproducibility of our 
data: 
• Standardised protocols for sample collection 
and processing based on previous testing of different 
centrifugation steps, tubes, sample types (serum or 
plasma) (data not shown and Supplementary Fig. S1A).
• Standardised protocols for RNA extraction 
based on previous optimisation of different sample 
input volumes (data not shown) and use of RNA carriers 
(Roche). As shown in Supplementary Fig. S1C, RNA 
carriers introduced a bias and were therefore not used in 
this study. 
• Spike-in controls of 3 exogenous C.elegans 
miRNAs (cel-39, cel-54, cel-238) [25] in 3 different 
concentrations were added to account for biases in 
quantification of miRNAs with low or high abundance 
and to control for quality of the serum sample RNA 
extraction (different spike-in ratios were previously 
tested, Supplementary Fig. S1B). Cel-39 expression was 
also analysed on the whole miRNome and custom qPCR 
arrays and its expression values were used to calibrate 
data for all serum samples. We are aware that spiked-in 
RNAs are not the perfect controls for the efficiency of 
RNA extraction [53, 54] but together with other controls 
(see below) it currently represents the best possible way to 
control miRNA quantification results.
• Thorough quality control RT-qPCRs were 
performed on each serum sample prior to analysis on 
qPCR arrays using all of the following primers: cel-39, 
cel-54, cel-238, miR-451a, miR-23a-5p, SNORD61, 
SNORD68, SNORD72, SNORD95, SNORD96A and 
RNU6-2 (details under “RNA extraction and RNA 
quality control). Samples not meeting QC standards were 
excluded from the study.
• Qiagen qPCR arrays with optional pre-
amplification were chosen as they have high quality 
scores compared to 11 other platforms [26]. The necessity 
of pre-amplification was established by comparing the 
positive calls on the qPCR arrays with and without this 
step (Supplementary Fig. S1D). Further, the introduced 
amplification factor was determined for specific miRNAs 
(Supplementary Fig. S1E). The qPCR arrays have default 
miRTC (internal reverse transcription control) and PPC 
(positive PCR control) spotted on each plate. Only plates 
with correct values for all internal controls were used for 
follow-up analysis.
• We compared the amplification efficiency 
of Qiagen miRNA qPCR arrays with manual qPCR 
amplifications for 11 selected primers (Supplementary Fig. 
S1F) and found a high correlation of results.
• Due to the absence of well-expressed and 
suitable reference miRNAs in serum that could be used 
for normalisation, we applied different normalisation 
methods. They were based either on means of commonly 
expressed miRNAs (“global mean method”, for whole 
miRNome qPCR arrays) or on “RefFinder” (for custom 
miRNA arrays), a webtool, which integrates results 
from geNorm, Normfinder, and BestKeeper as well as 
the comparative ΔΔCt method to determine the 5 most 
stable miRNAs in each data set (http://www.leonxie.com/
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referencegene.php).
• A healthy serum miRNome was compiled to allow 
for better comparison with cancer samples (Fig. 2 and 
Supplementary Table S2).
• Since there is not much known about the 
consistency or differences of miRNAs expressed in tissue 
versus circulation, we compared in 4 individuals patterns 
of circulating miRNAs to their tissue samples (Fig. 5 
and Supplementary Fig. S3). We tried to quantify RNA 
extracted from serum using Nanodrop (ThermoScientific) 
and HighSens quantification chips (BioRad) but had no 
consistent results. Therefore, the amount of input material 
for reverse transcription from serum samples may vary 
and be less consistent than input amounts from tissue-
derived samples where RNA quantification is possible.
• A total of 126 samples (melanoma and healthy 
controls, whole miRNome and custom profiling) were 
used as well as more miRNAs than are usually tested 
(starting from whole miRNomes, with 1066 miRNAs v.16 
down to 88 selected miRNAs on custom plates). 
Sample collection
In order to minimize variability derived from 
sample collection and handling, a standard procedure 
was developed that was strictly adhered to for all sample 
collection and processing steps. After blood withdrawal, 
serum tubes were left at room temperature for 1 hour; 
samples were then centrifuged for 15 min at 2000 rpm 
(750 g) at room temperature. Subsequently the serum was 
removed, aliquoted, snap-frozen and stored at -80°C until 
RNA extraction. Whole blood was collected in PAXgene 
Blood RNA tubes (BD Biosciences) according to the 
manufacturer’s instructions and stored at -80°C until RNA 
extraction. Primary melanoma, melanoma metastasis, as 
well as the corresponding healthy skin were excised and 
immediately stored at –80°C until further use. Staging of 
diseases was performed by the histology departments of 
the respective clinics. 
Total RNA extraction and RNA quality control
To extract total RNA from whole blood, the 
PAXgene blood miRNA kit (PreAnalytiX) was used. 
Total RNA from NHEM, NHEK and A375 cells was 
extracted using the miRNeasy Mini kit according to 
the manufacturer´s instructions. Tissues (primary and 
metastatic melanoma and healthy skin) were lysed in 
RLT Plus buffer with the TissueLyser LT (Qiagen) and 
total RNA was extracted with AllPrep DNA/RNA Mini 
kit (Qiagen) according to the manufacturer’s instructions. 
Eluted RNA was subsequently processed by standard 
ethanol precipitation. Quantity and purity of whole blood, 
tissue and cell line RNA were assessed using a Nanodrop 
ND-2000 Spectrophotometer.
Total RNA from 200 μl serum was extracted using 
the miRNeasy serum/plasma kit (Qiagen) according to 
the manufacturer’s instructions. Before the addition of 
Qiazol, the serum was thawn at room temperature and 
centrifuged for 30 min at 13000 rpm (16000 g) at 4°C to 
remove cellular debris. As an internal calibrator, a mix of 
cel-39, cel-54 and cel-238 exogenous controls was spiked 
into the samples. RNA was eluted with 14 μl of RNase-
free water. Quality control of serum RNA was performed 
by RT-qPCR using primers for: 
• Cel-39, cel-54, cel-238 spikes to control for 
variations in recovery and amplification efficiency 
between RNA preparations
• miR-451a (highly expressed in blood cells, [19, 
55]) and miR-23a-5p (relatively stable in serum and not 
affected by hemolysis) to calculate a hemolysis indicator 
[27] 
• SNORD61, SNORD68, SNORD72, SNORD95, 
SNORD96A and RNU6-2 highly expressed in blood cells 
and normally absent in serum to control for blood cell 
contamination of the serum (Qiagen White paper, Shaffer 
et al., 2012).
Briefly, 4 μl out of 12 μl eluted total RNA from 
200 μl serum were reverse transcribed in a 10 μl reaction 
volume with the miScript RT II kit (Qiagen) following the 
supplied protocol using Hispec buffer, which specifically 
amplifies only mature miRNAs. Real-time PCR detection 
of the above-mentioned mature miRNAs was carried out 
on a CFX96 Detection System (Bio-Rad) using 1 μl of 
1:10 diluted cDNA, 2x iQ SYBR Green Supermix (Bio-
Rad) and 10× miRNA-specific primer assay (Qiagen). 
Specificity of the qPCR primers was assessed by a post-
qPCR melting curve analysis. All serum samples were 
quality controlled in the above described way. Samples 
not reaching sufficient quality metrics due to hemolysis, 
white blood cell contamination or incomplete recovery of 
spiked-in controls were excluded from the study (31 of a 
total of 131 serum samples). 
miRNA profiling by qPCR arrays 
Due to generally low amounts of miRNAs in 
serum samples, we opted for a pre-amplification step for 
all samples (see Supplementary Fig. S1D). MiRNAs of 
serum, whole blood, tissues and cell lines were profiled 
with human whole miRNome miScript miRNA qPCR 
arrays (Qiagen, v.16, 1066 miRNAs) or on custom qPCR 
arrays (Qiagen). For serum, 4 μl out of 12 μl eluted total 
RNA from 200 μl serum, and for tissue, whole blood and 
cell lines 50 or 100 ng RNA were reverse transcribed 
in a 10 μl reaction volume with the miScript RT II kit 
(Qiagen) using Hispec buffer. Regarding serum pools, 
corresponding RNA samples were pooled and 4 μl of 
pooled total RNA were reverse transcribed as described 
above. The 1:5 diluted cDNA was pre-amplified with 
the miScript PreAMP PCR kit (Qiagen) using the 
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corresponding primer mixes (whole miRNome primer 
mix for whole miRNome qPCR arrays and custom primer 
mix for custom qPCR arrays). Pre-amplification control 
experiments were performed by RT-qPCR using primer 
assays for miR-16-5p, SNORD95, cel-39 and miRTC 
(internal miRNA reverse transcription control). Quality 
controlled pre-amplified cDNA was diluted 1:5 and 
further used for miScript whole miRNome and custom 
qPCR arrays (Qiagen). All kits and qPCR arrays were 
used according to the supplied protocols. Real-time 
PCR detection on the qPCR arrays was carried out on a 
CFX384 Detection System (Bio-Rad). Specificity of the 
qPCR primers was assessed by a post-qPCR melting 
curve analysis (see below). The selection process of 
primer assays to be spotted on the custom qPCR arrays is 
described in the Methods section and in Fig. 1. Raw data 
files of all qPCR arrays are available upon request.
Data analysis
For qPCR array data analysis, baselines and 
thresholds were adjusted as recommended by the supplier 
and Cq values were exported for analysis. Cq values 
obtained with the cel-39 primers were used to calibrate 
the data sets: the Cq mean for cel-39 for each sample 
was calculated, the highest Cq mean of all samples was 
determined and the difference (correction factor) with the 
other samples was established. This correction factor was 
added to all Cq values of a sample. Calibrated Cq values 
greater than 30, as well as primers with bad melting curves 
(see below) were considered as not detected (N/A). These 
lower cut-off Cq values, recommended by the supplier, 
are due to the additional 12 PCR cycles during pre-
amplification. Because of the lack of established house-
keeping genes in serum imperative for data normalization, 
we used means of commonly expressed miRNAs (for 
whole miRNome qPCR arrays) or the 5 most stable 
miRNAs individually determined by RefFinder (see 
above). 
Quality control of qPCR melting curves
To assess the quality of melting curves from the 
whole miRNome qPCRs, we have developed a Support 
Vector Machine (SVM)-based method based on the R 
‘e1071’ package, which is available upon request. Our 
tool is able to recognize “good” and “bad” curves, based 
on their shapes and curve features such as the Cq values, 
the melting temperatures, the peak heights, and the starting 
and end temperatures. All information was extracted from 
the Biorad run files from which post run melting curves 
were obtained. 6847 manually annotated and controlled 
curves were used as a training set. To assess the efficiency 
of this method, one third (2281) of this set was removed 
before training. Then the ROC score was computed for 
this training/test set combination. This process was 
repeated 100 times and an average ROC score was 
calculated to compute how efficient the classifiers were 
(ROC score: 0.988). After training with the full training 
set, melting curves were predicted by our tool. Although 
the ROC score obtained during the evaluation was very 
high, we wanted to keep a degree of manual inspection 
as an additional control step. In addition to the “good” 
or “bad” labelling, our tool calculated the probability of 
prediction of each curve computed by the SVM. If this 
probability was below the mean minus one standard 
deviation of all the probabilities of prediction, the label 
of the curve became “questionable”, which means it had 
to be inspected manually. All other curves were labelled 
according to the SVM prediction in “good” (specific 
amplification) or bad (unspecific amplification, even if Cq 
<30 were scored).
Biomarker signature
To determine whether signatures of miRNAs could 
classify patients with respect of the different stages, 9 
stage comparisons were investigated: (a) healthy versus 
melanoma, (b) healthy versus stage 0, (c) healthy versus 
stage I, (d) healthy versus stage II, (e) healthy versus 
stage III, (f) healthy versus stage IV, (g) healthy versus 
stages 0+I+II, (h) healthy versus stages III+IV, (i) stages 
0+I+II versus stages III+IV. For each of them, a dataset 
containing only patients at those stages was built. When a 
group contained more than one stage, the different stages 
were designated by a common label, e.g. 0+I+II become 
“early stage”.
For each comparison, to find the signature that had 
the best stage discrimination, the following procedure 
was followed: miRNAs were ranked with respect to their 
importance in stage classification by a SVM classifier, 
according to the SVM-RFE method [56]. Then, signatures 
from 2 to 10 miRNAs were built by adding one miRNA, 
by order of discriminative power, to the signature (e.g. a 
signature of 2 miRNAs contained the most discriminative 
miRNA and the second most discriminative miRNA, a 
signature of 3 miRNAs contains the previous signature 
plus the third most discriminative miRNA according to 
the SVM-RFE). 
The ability of each signature to classify patients by 
stage was evaluated through a leave-one-out procedure, 
i.e. each patient of the set was predicted once by using 
all other patients as training set for a SVM classifier. The 
accuracy of classification was determined by counting 
the number of correct assignments out of the number of 
patients in the set. The signature with the highest accuracy 
was considered as best miRNA signature. Accuracy values 
are indicated for information in Fig. 4B. For this signature 
a ROC curve was determined by taking half of the patients 
as training set for a SVM classifier (the other half is used 
as test set). Note that ranking by the SVM-RFE algorithm 
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is specific to each training set. Combined datasets (e.g. S 
III+IV) may yield different information when compared 
to individual datasets. All SVM training and classification 
have been made using the R package (e1071) and ROC 
curves have been generated with the pROC package [57].
Visualization
The heatmaps were created using heatmap.2 
function from R Bioconductor package gplots. For 
generating heatmaps expression values were log2 
transformed. MiRNAs that were absent in all samples are 
not depicted. Principal component analysis (PCA) was 
performed using R Bioconductor. t-SNE dimensionality 
reduction [58] was performed using the tsne package from 
R Bioconductor specifying the perplexity parameter to 10 
and using the whiten option. 
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